Alene Kennedy-Hendricks1,2, Cameron J Schilling3,4, Alisa B Busch5,6, Elizabeth A Stuart4,7, Haiden A Huskamp5, Mark K Meiselbach3, Colleen L Barry3,4,7, Matthew D Eisenberg3,4,8. 1. Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, 624 N. Broadway, Hampton House 408, Baltimore, MD, 21205, USA. alene@jhu.edu. 2. Johns Hopkins Center for Mental Health and Addiction Policy, Baltimore, MD, USA. alene@jhu.edu. 3. Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, 624 N. Broadway, Hampton House 408, Baltimore, MD, 21205, USA. 4. Johns Hopkins Center for Mental Health and Addiction Policy, Baltimore, MD, USA. 5. Department of Health Care Policy, Harvard Medical School, Boston, MA, USA. 6. McLean Hospital, Belmont, MA, USA. 7. Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. 8. OptumLabs, Cambridge, MA, USA.
Abstract
BACKGROUND: Long-term, continuous treatment with medication like buprenorphine is the gold standard for opioid use disorder (OUD). As high deductible health plans (HDHPs) become more prevalent in the commercial insurance market, they may pose financial barriers to people with OUD. OBJECTIVE: To estimate the impact of HDHPs on continuity of buprenorphine treatment, concurrent visits for counseling/psychotherapy and OUD-related evaluation and management, and out-of-pocket spending. DESIGN: Difference-in-differences analysis comparing trends in outcomes among enrollees whose employers offer an HDHP (treatment group) to enrollees whose employers never offer an HDHP (comparison group). PARTICIPANTS: Enrollees with OUD from a national sample of commercial health insurance plans during 2007-2017 who initiate buprenorphine treatment. MAIN MEASURES: Number of days of continuous buprenorphine treatment; probabilities of continuous buprenorphine treatment ≥30, ≥90, ≥180, and ≥365 days; probability of concurrent (i.e., within the same month) behavioral therapy (i.e., counseling or psychotherapy); probability of concurrent OUD-related evaluation and management visits; proportions of buprenorphine treatment episodes with counseling/psychotherapy and evaluation and management visits; and out-of-pocket (OOP) spending on buprenorphine, behavioral therapy, and evaluation and management visits. KEY RESULTS: HDHPs were associated with an average increase of $98 (95% CI: $48, $150) on OOP spending on buprenorphine per treatment episode but no change in the number of days of continuous buprenorphine treatment or concurrent use of related services. CONCLUSIONS: HDHPs do not reduce continuity of buprenorphine treatment among commercially insured enrollees with OUD but may increase financial burden for this population.
BACKGROUND: Long-term, continuous treatment with medication like buprenorphine is the gold standard for opioid use disorder (OUD). As high deductible health plans (HDHPs) become more prevalent in the commercial insurance market, they may pose financial barriers to people with OUD. OBJECTIVE: To estimate the impact of HDHPs on continuity of buprenorphine treatment, concurrent visits for counseling/psychotherapy and OUD-related evaluation and management, and out-of-pocket spending. DESIGN: Difference-in-differences analysis comparing trends in outcomes among enrollees whose employers offer an HDHP (treatment group) to enrollees whose employers never offer an HDHP (comparison group). PARTICIPANTS: Enrollees with OUD from a national sample of commercial health insurance plans during 2007-2017 who initiate buprenorphine treatment. MAIN MEASURES: Number of days of continuous buprenorphine treatment; probabilities of continuous buprenorphine treatment ≥30, ≥90, ≥180, and ≥365 days; probability of concurrent (i.e., within the same month) behavioral therapy (i.e., counseling or psychotherapy); probability of concurrent OUD-related evaluation and management visits; proportions of buprenorphine treatment episodes with counseling/psychotherapy and evaluation and management visits; and out-of-pocket (OOP) spending on buprenorphine, behavioral therapy, and evaluation and management visits. KEY RESULTS: HDHPs were associated with an average increase of $98 (95% CI: $48, $150) on OOP spending on buprenorphine per treatment episode but no change in the number of days of continuous buprenorphine treatment or concurrent use of related services. CONCLUSIONS: HDHPs do not reduce continuity of buprenorphine treatment among commercially insured enrollees with OUD but may increase financial burden for this population.
Authors: Sarah E Wakeman; Marc R Larochelle; Omid Ameli; Christine E Chaisson; Jeffrey Thomas McPheeters; William H Crown; Francisca Azocar; Darshak M Sanghavi Journal: JAMA Netw Open Date: 2020-02-05
Authors: Sheila K Reiss; Dennis Ross-Degnan; Fang Zhang; Stephen B Soumerai; Alan M Zaslavsky; J Frank Wharam Journal: Health Serv Res Date: 2011-03-17 Impact factor: 3.402
Authors: J Frank Wharam; Alisa B Busch; Jeanne Madden; Fang Zhang; Matthew Callahan; Robert F LeCates; Phyllis Foxworth; Stephen Soumerai; Dennis Ross-Degnan; Christine Y Lu Journal: Am J Manag Care Date: 2020-06 Impact factor: 2.229
Authors: Cameron J Schilling; Matthew D Eisenberg; Alene Kennedy-Hendricks; Alisa B Busch; Haiden A Huskamp; Elizabeth A Stuart; Mark K Meiselbach; Colleen L Barry Journal: Psychiatr Serv Date: 2021-09-30 Impact factor: 4.157
Authors: A Mark Fendrick; Jason D Buxbaum; Yuexin Tang; Anna Vlahiotis; Donna McMorrow; Swapnil Rajpathak; Michael E Chernew Journal: JAMA Netw Open Date: 2019-11-01